

# Efficacy and effectiveness of an rVSV-vectored vaccine glycoprotein: interim results from the Guinea ring vacc

Lancet, The

386, 857-866

DOI: [10.1016/s0140-6736\(15\)61117-5](https://doi.org/10.1016/s0140-6736(15)61117-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update From the Advisory Committee on Immunization Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 282-285.	0.6	12
3	Ebola vaccination – Authors' reply. <i>Lancet, The</i> , 2015, 386, 2480.	6.3	5
4	Ebola vaccination. <i>Lancet, The</i> , 2015, 386, 2478-2480.	6.3	0
5	'Back to the future' – from 2015 to 2016. <i>Public Health</i> , 2015, 129, 1551-1552.	1.4	1
6	Look to Poland! Conversion from opportunistic screening to a randomized, national screening program for colorectal cancer. <i>Endoscopy</i> , 2015, 47, 1104-1105.	1.0	0
7	Clinical Management of Ebola Virus Disease: Current and Future Approaches. <i>Topics in Medicinal Chemistry</i> , 2015, , 1-36.	0.4	0
8	Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach. <i>BMJ Open</i> , 2015, 5, e009346.	0.8	22
9	Preliminary success of international efforts to tackle the Ebola virus. <i>NursePrescribing</i> , 2015, 13, 474-475.	0.1	0
10	How can health systems be strengthened to control and prevent an Ebola outbreak? A narrative review. <i>Infection Ecology and Epidemiology</i> , 2015, 5, 28877.	0.5	20
11	Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 1641-1658.	1.1	8
12	Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. <i>BMC Medicine</i> , 2015, 13, 271.	2.3	33
13	The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions. <i>BMC Medicine</i> , 2015, 13, 281.	2.3	50
14	Communicate, educate: tackling misconceptions to boost vaccine uptake. <i>Future Virology</i> , 2015, 10, 1029-1032.	0.9	0
16	Conflicts of interest in medical publishing: it's all about trustworthiness. <i>British Journal of Dermatology</i> , 2015, 173, 1255-1257.	1.4	5
17	The Ebola Vaccine, Iatrogenic Injuries, and Legal Liability. <i>PLoS Medicine</i> , 2015, 12, e1001911.	3.9	4
18	The Economics of Epidemic Diseases. <i>PLoS ONE</i> , 2015, 10, e0137964.	1.1	9
19	Evaluating Subcriticality during the Ebola Epidemic in West Africa. <i>PLoS ONE</i> , 2015, 10, e0140651.	1.1	6
20	Disease outbreak: Finish the fight against Ebola. <i>Nature</i> , 2015, 524, 27-29.	13.7	8

#	ARTICLE	IF	CITATIONS
21	Successful Ebola vaccine provides 100% protection in trial. Nature, 2015, , .	13.7	1
22	International Congress on Targeting Ebola 28â€“29 May 2015, Pasteur Institute, Paris. Journal of Virus Eradication, 2015, 1, 282-283.	0.3	1
23	Ebola vaccine R&D: Filling the knowledge gaps. Science Translational Medicine, 2015, 7, 317ps24.	5.8	41
24	2015 in Review. Nature Medicine, 2015, 21, 1380-1381.	15.2	0
25	Notable advances 2015. Nature Medicine, 2015, 21, 1384-1386.	15.2	0
26	Ebola: Europeâ€“Africa research collaborations. Lancet Infectious Diseases, The, 2015, 15, 1258-1259.	4.6	10
27	Ebola vaccination. Lancet, The, 2015, 386, 2478.	6.3	2
29	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. Cell, 2015, 163, 988-998.	13.5	326
30	Clinical development of Ebola vaccines. Therapeutic Advances in Vaccines, 2015, 3, 125-138.	2.7	65
31	Era of global Ebola: risk of exposure in health-care workers. Lancet Infectious Diseases, The, 2015, 15, 1248-1249.	4.6	5
32	Ebola virus vaccinesâ€“preparing for the unexpected. Science, 2015, 349, 693-694.	6.0	4
34	Ebola vaccine trial falls short of homerun. Nature Biotechnology, 2015, 33, 1011-1012.	9.4	0
35	Speeding up epidemic emergency response. Science, 2015, 350, 170-170.	6.0	2
36	Editorial overview: Vaccines: Vaccines for cancer and infectious diseases. Current Opinion in Immunology, 2015, 35, v-vii.	2.4	1
37	Ebola vaccine trial results are â€œextremely promising,â€•says WHO. BMJ, The, 2015, 351, h4192.	3.0	1
39	Interim results from a phase 3 Ebola vaccine study in Guinea. Lancet, The, 2015, 386, 831-833.	6.3	26
40	Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola. Lancet, The, 2015, 386, 2204-2221.	6.3	437
41	Getting the most from the Ebola vaccine success. Vaccine, 2015, 33, 7141.	1.7	0

#	ARTICLE	IF	CITATIONS
42	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	3
43	West Africa 2013: Re-examining Ebola. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	16
44	Inter-Philosophies Dialogue: Creating a Paradigm for Global Health Ethics. <i>Kennedy Institute of Ethics Journal</i> , 2016, 26, 323-346.	0.3	50
45	Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic. <i>Risk Management and Healthcare Policy</i> , 2016, 9, 55.	1.2	8
46	Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease. <i>Emerging Infectious Diseases</i> , 2016, 22, 105-108.	2.0	83
47	Ebola and Its Control in Liberia, 2014-2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 169-177.	2.0	59
48	Ebola virus - from neglected threat to global emergency state. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 458-467.	0.3	1
49	Broadly neutralizing antibodies for therapy of viral infections. <i>Antibody Technology Journal</i> , 2016, , 1.	0.0	2
50	How are Vaccines Assessed in Clinical Trials?. , 2016, , 97-119.		0
51	Critiquing the response to the Ebola epidemic through a Primary Health Care Approach. <i>BMC Public Health</i> , 2016, 16, 410.	1.2	38
52	The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan. <i>PLoS Medicine</i> , 2016, 13, e1001994.	3.9	92
53	Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004866.	1.3	4
54	Containing Ebola at the Source with Ring Vaccination. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005093.	1.3	54
55	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
56	Antigen Production in Plant to Tackle Infectious Diseases Flare Up: The Case of SARS. <i>Frontiers in Plant Science</i> , 2016, 7, 54.	1.7	31
57	Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2016, 34, 6597-6609.	1.7	53
59	The International Health Regulations: The Governing Framework for Global Health Security. <i>Milbank Quarterly</i> , 2016, 94, 264-313.	2.1	107
60	Virus-based nanoparticles as platform technologies for modern vaccines. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2016, 8, 554-578.	3.3	55

#	ARTICLE	IF	CITATIONS
61	Public Health Surveillance: At the Core of the Global Health Security Agenda. <i>Health Security</i> , 2016, 14, 185-188.	0.9	53
62	Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. <i>Scientific Reports</i> , 2016, 6, 27944.	1.6	72
63	Parental Presence During Treatment of Ebola or Other Highly Consequential Infection. <i>Pediatrics</i> , 2016, 138, .	1.0	20
64	Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. <i>Scientific Reports</i> , 2016, 6, 23803.	1.6	20
65	Spreading alcohol brief interventions from health care to non-health care settings: Is it justified?. <i>Drugs: Education, Prevention and Policy</i> , 2016, 23, 359-364.	0.8	5
66	Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. <i>Journal of Infectious Diseases</i> , 2016, 214, S497-S499.	1.9	33
67	Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research. <i>Journal of Medical Ethics</i> , 2016, 42, 797-804.	1.0	16
68	Carrion's disease: an eradicable illness?. <i>Infectious Diseases of Poverty</i> , 2016, 5, 105.	1.5	21
69	Responding to ever-changing epidemiological dynamics of Ebola virus disease. <i>BMJ Global Health</i> , 2016, 1, e000180.	2.0	2
70	Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw793.	2.9	70
71	The permuted locus trial's Well suited for emerging pathogens?. <i>Contemporary Clinical Trials</i> , 2016, 47, 72-73.	0.8	0
72	Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine. <i>Npj Vaccines</i> , 2016, 1, .	2.9	26
73	Both Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like Domain. <i>Journal of Virology</i> , 2016, 90, 5475-5484.	1.5	18
74	Vaccinology in the third millennium: scientific and social challenges. <i>Current Opinion in Virology</i> , 2016, 17, 116-125.	2.6	28
75	Vaccines against the other Ebola virus species. <i>Expert Review of Vaccines</i> , 2016, 15, 1093-1100.	2.0	6
76	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw031.	0.4	13
77	Ebola response in Sierra Leone: The impact on children. <i>Journal of Infection</i> , 2016, 72, S6-S12.	1.7	19
78	Parental Presence at the Bedside of a Child with Suspected Ebola: An Expert Discussion. <i>Clinical Pediatric Emergency Medicine</i> , 2016, 17, 81-86.	0.4	6

#	ARTICLE	IF	CITATIONS
79	Changes in the primary outcome in Ebola vaccine trial. <i>Lancet, The</i> , 2016, 387, 1509.	6.3	4
80	Changes in the primary outcome in Ebola vaccine trial – Authors' reply. <i>Lancet, The</i> , 2016, 387, 1509-1510.	6.3	5
81	Vaccine platforms to control Lassa fever. <i>Expert Review of Vaccines</i> , 2016, 15, 1135-1150.	2.0	33
82	Ebola virus vaccines – reality or fiction?. <i>Expert Review of Vaccines</i> , 2016, 15, 1421-1430.	2.0	29
83	Safety and Immunogenicity of Novel Adenovirus Type 26 – and Modified Vaccinia Ankara – Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
84	Ebola virus encodes a miR-155 analog to regulate importin- $\beta$ 5 expression. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3733-3744.	2.4	29
85	Status of vaccine research and development of vaccines for Nipah virus. <i>Vaccine</i> , 2016, 34, 2971-2975.	1.7	76
86	Randomized controlled trials in the West African Ebola virus outbreak. <i>Clinical Trials</i> , 2016, 13, 10-12.	0.7	11
87	Establishing herd immunity against Ebola through vaccination. <i>Vaccine</i> , 2016, 34, 2644-2647.	1.7	14
88	Safe treatment of health-care workers with Ebola. <i>British Journal of Anaesthesia</i> , 2016, 116, 577-579.	1.5	2
89	Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. <i>Clinical Infectious Diseases</i> , 2016, 63, 376-379.	2.9	26
90	A US Food and Drug Administration perspective on evaluating medical products for Ebola. <i>Clinical Trials</i> , 2016, 13, 105-109.	0.7	10
91	Ebola virus disease candidate vaccines under evaluation in clinical trials. <i>Expert Review of Vaccines</i> , 2016, 15, 1101-1112.	2.0	50
92	On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014 – 2016 Ebola epidemic in West Africa. <i>Current Opinion in Virology</i> , 2016, 17, 138-144.	2.6	48
93	Zika vaccine trials. <i>Science</i> , 2016, 353, 1094-1095.	6.0	7
94	Ebola vaccines – Where are we?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2700-2703.	1.4	3
95	When should antiviral drugs be used for the patient with an Ebola virus infection?. <i>International Journal of Infectious Diseases</i> , 2016, 50, 21-22.	1.5	0
96	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	2.5	97

#	ARTICLE	IF	CITATIONS
97	Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opinion on Investigational Drugs, 2016, 25, 1325-1335.	1.9	34
101	Down to the Molecular Mechanisms of Host-Pathogen Interactions. Journal of Molecular Biology, 2016, 428, 3353-3354.	2.0	2
102	Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. Journal of Infectious Diseases, 2016, 214, S360-S366.	1.9	62
103	Ebola Ring-Vaccine Trial Was Ethically Innovative. American Journal of Public Health, 2016, 106, e1-e1.	1.5	2
104	Health-Care Workers' Perspectives on Ebola Virus Vaccine: A Focus Group and In-Depth Interview Interventional Study. American Journal of Tropical Medicine and Hygiene, 2016, 95, 654-662.	0.6	10
105	Response to Comment on "Mutation rate and genotype variation of Ebola virus from Mali case sequences". Science, 2016, 353, 658-658.	6.0	4
106	Molecular mechanisms of Ebola pathogenesis. Journal of Leukocyte Biology, 2016, 100, 889-904.	1.5	31
107	New Vaccines on the Horizon. Current Pediatrics Reports, 2016, 4, 74-83.	1.7	0
108	Neurological Complications of Ebola Virus Infection. Neurotherapeutics, 2016, 13, 461-470.	2.1	44
109	Epidemiology and Management of the 2013-16 West African Ebola Outbreak. Annual Review of Virology, 2016, 3, 147-171.	3.0	28
110	BoHV-4-based vector delivering Ebola virus surface glycoprotein. Journal of Translational Medicine, 2016, 14, 325.	1.8	8
111	In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 5388-5392.	1.4	15
112	The Density Code for the Development of a Vaccine?. Journal of Pharmaceutical Sciences, 2016, 105, 3223-3232.	1.6	22
113	Ebola Virus Makona Shows Reduced Lethality in an Immune-deficient Mouse Model. Journal of Infectious Diseases, 2016, 214, S268-S274.	1.9	16
114	An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. Journal of Infectious Diseases, 2016, 214, S342-S354.	1.9	32
115	Modeling Ring-Vaccination Strategies to Control Ebola Virus Disease Epidemics. , 2016, , 71-87.		6
117	Leadership in Times of Crisis: The Example of Ebola Virus Disease in Liberia. Health Systems and Reform, 2016, 2, 194-207.	0.6	43
118	Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 2016, 6, 25856.	1.6	46

#	ARTICLE	IF	CITATIONS
119	Willingness to participate in Ebola viral disease vaccine trials and receive vaccination by health workers in a tertiary hospital in Ile-Ife, Southwest Nigeria. <i>Vaccine</i> , 2016, 34, 5758-5761.	1.7	1
120	Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. <i>Scientific Reports</i> , 2016, 6, 33987.	1.6	35
121	Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 21674.	1.6	54
122	Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16021.	2.0	63
123	Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. <i>Nature Microbiology</i> , 2016, 1, 16164.	5.9	75
124	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. <i>Nature Microbiology</i> , 2016, 1, 16128.	5.9	92
125	Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. <i>Nature Medicine</i> , 2016, 22, 1439-1447.	15.2	78
126	Epidemiology: Making high-res Zika maps. <i>Nature Microbiology</i> , 2016, 1, 16157.	5.9	6
127	Ebola virus vaccines: Where do we stand?. <i>Clinical Immunology</i> , 2016, 173, 44-49.	1.4	32
131	A web-based resource for designing therapeutics against Ebola Virus. <i>Scientific Reports</i> , 2016, 6, 24782.	1.6	14
132	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	1
133	Optimal control analysis of Ebola disease with control strategies of quarantine and vaccination. <i>Infectious Diseases of Poverty</i> , 2016, 5, 72.	1.5	37
134	Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis. <i>BMC Medicine</i> , 2016, 14, 130.	2.3	30
135	Ebola virus disease and the eye. <i>Current Opinion in Ophthalmology</i> , 2016, 27, 538-544.	1.3	16
136	Clinical Research and the Training of Host Country Investigators: Essential Health Priorities for Disease-Endemic Regions. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 253-257.	0.6	7
137	How to Confront the Threat of Ebola? Arguing for Reinforced Efforts to Promote Transnational Solidarity. <i>Global Policy</i> , 2016, 7, 340-350.	1.0	3
138	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	2.4	137
139	Neoliberal policy, chronic corruption and disablement: biosecurity, biosocial risks and the creation of "Ebola survivors"? <i>Disability and Society</i> , 2016, , 1-5.	1.4	1



#	ARTICLE	IF	CITATIONS
140	Evaluating interventions for Ebola: The need for randomized trials. <i>Clinical Trials</i> , 2016, 13, 6-9.	0.7	13
141	Statistics and logistics: Design of Ebola vaccine trials in West Africa. <i>Clinical Trials</i> , 2016, 13, 87-91.	0.7	11
142	Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation. <i>Clinical Trials</i> , 2016, 13, 66-72.	0.7	12
143	Ethical challenges to responding to the Ebola epidemic: the World Health Organization experience. <i>Clinical Trials</i> , 2016, 13, 96-100.	0.7	17
144	The 2014â€“2015 Ebola outbreak in West Africa: Hands On. <i>Antimicrobial Resistance and Infection Control</i> , 2016, 5, .	1.5	55
145	Lessons learned? Ebola, dietary salt reduction and epigenetics. <i>International Journal of Epidemiology</i> , 2016, 45, 1-3.	0.9	13
146	Ebola vaccine development plan: ethics, concerns and proposed measures. <i>BMC Medical Ethics</i> , 2016, 17, 10.	1.0	26
147	Ethical Rationale for the Ebola â€œRing Vaccinationâ€•Trial Design. <i>American Journal of Public Health</i> , 2016, 106, 432-435.	1.5	37
148	The Ethics of Infection Challenges in Primates. <i>Hastings Center Report</i> , 2016, 46, 20-26.	0.7	14
149	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
151	Update From the Advisory Committee on Immunization Practices: Table 1.. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 3-6.	0.6	0
152	Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , 2016, 45, 102-116.	0.9	81
153	Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response. <i>EcoHealth</i> , 2016, 13, 200-212.	0.9	64
154	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> . The, 2016, 16, 31-42.	4.6	187
155	Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4488-4493.	3.3	70
156	Beyond Ebola. <i>Science</i> , 2016, 351, 815-816.	6.0	19
157	Ebola virus disease: emergence, outbreak and future directions. <i>British Medical Bulletin</i> , 2016, 117, 95-106.	2.7	21
158	Stability of a Vesicular Stomatitis Virusâ€“Vectored Ebola Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 213, 930-933.	1.9	21

#	ARTICLE	IF	CITATIONS
159	Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 907-923.	1.6	135
160	Taking the bull by the horns: Ethical considerations in the design and implementation of an Ebola virus therapy trial. <i>Social Science and Medicine</i> , 2016, 148, 163-170.	1.8	12
162	Clinical research during the Ebola virus disease outbreak in Guinea: Lessons learned and ways forward. <i>Clinical Trials</i> , 2016, 13, 73-78.	0.7	14
163	Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1277-1286.	2.9	71
164	Development of immuno-oncology drugs “ from CTLA4 to PD1 to the next generations. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 235-247.	21.5	503
165	Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 311-320.	4.6	133
166	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. <i>Virus Research</i> , 2016, 213, 224-229.	1.1	23
167	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213.	7.0	148
168	Preventive malaria treatment for contacts of patients with Ebola virus disease in the context of the west Africa 2014-15 Ebola virus disease response: an economic analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 449-458.	4.6	11
169	Ebola vaccines: we have options. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 267-268.	4.6	3
170	Did Neoliberalizing West African Forests Produce a New Niche for Ebola?. <i>International Journal of Health Services</i> , 2016, 46, 149-165.	1.2	19
171	The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e1-e9.	4.6	18
172	Ebola: what it teaches us about medical ethics. A response to Angus Dawson. <i>Journal of Medical Ethics</i> , 2016, 42, 59-60.	1.0	6
173	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	13.9	355
174	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
175	Handle Survivors with Care. <i>New England Journal of Medicine</i> , 2017, 377, 1480-1482.	13.9	12
176	Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1403.	3.3	34
177	New Vaccines against Epidemic Infectious Diseases. <i>New England Journal of Medicine</i> , 2017, 376, 610-613.	13.9	70

#	ARTICLE	IF	CITATIONS
178	CEPIâ€”a new global R&D organisation for epidemic preparedness and response. <i>Lancet</i> , The, 2017, 389, 233-235.	6.3	100
179	Immunobiology of Ebola and Lassa virus infections. <i>Nature Reviews Immunology</i> , 2017, 17, 195-207.	10.6	95
180	Ebola: lessons learned. <i>Paediatrics and Child Health (United Kingdom)</i> , 2017, 27, 128-134.	0.2	2
181	Ebola outbreak preparedness planning: a qualitative study of clinicians' experiences. <i>Public Health</i> , 2017, 143, 103-108.	1.4	15
182	Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 613-620.	1.4	92
183	Experimental Therapies for Ebola Virus Disease: What Have We Learned?. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw496.	1.9	23
184	Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
185	Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 545-552.	4.6	96
186	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i> ][triazin-4-amino] Adenine <i>C</i> -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	2.9	547
187	Offering general pediatric care during the hard times of the 2014 Ebola outbreak: looking back at how many came and how well they fared at a MÃ©decins Sans FrontiÃ¨res referral hospital in rural Sierra Leone. <i>BMC Pediatrics</i> , 2017, 17, 34.	0.7	8
188	Vaccine development for emerging virulent infectious diseases. <i>Vaccine</i> , 2017, 35, 5437-5443.	1.7	28
189	Ebola and Marburg: Out of Africa. , 2017, , 131-154.		0
190	Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017, 46, 176-182.	6.6	79
191	Leveraging contact network structure in the design of cluster randomized trials. <i>Clinical Trials</i> , 2017, 14, 37-47.	0.7	12
192	Global research trends of World Health Organizationâ€™s top eight emerging pathogens. <i>Globalization and Health</i> , 2017, 13, 9.	2.4	144
193	Generating Recombinant Vesicular Stomatitis Viruses for Use as Vaccine Platforms. <i>Methods in Molecular Biology</i> , 2017, 1581, 203-222.	0.4	7
194	The contribution of biological, mathematical, clinical, engineering and social sciences to combatting the West African Ebola epidemic. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160293.	1.8	12
195	Vaccine testing for emerging infections: the case for individual randomisation. <i>Journal of Medical Ethics</i> , 2017, 43, 625-631.	1.0	12

#	ARTICLE	IF	CITATIONS
197	Key data for outbreak evaluation: building on the Ebola experience. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160371.	1.8	70
198	The 2013–2016 Ebola epidemic: multidisciplinary success conceals a missed opportunity. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160292.	1.8	1
199	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	1.8	33
200	A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	48
201	An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein. <i>Scientific Reports</i> , 2017, 7, 45886.	1.6	8
202	Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. <i>International Journal of STD and AIDS</i> , 2017, 28, 1352-1359.	0.5	5
203	Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection. <i>Scientific Reports</i> , 2017, 7, 919.	1.6	31
204	Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout. <i>Vaccine</i> , 2017, 35, 5481-5486.	1.7	8
205	Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. <i>Clinical Trials</i> , 2017, 14, 201-210.	0.7	4
206	Progress in Ebola Virus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2017, 215, 1775-1776.	1.9	2
207	The science behind One Health: at the interface of humans, animals, and the environment. <i>Annals of the New York Academy of Sciences</i> , 2017, 1395, 12-32.	1.8	26
208	Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine. <i>Current Opinion in Virology</i> , 2017, 23, 88-94.	2.6	25
209	Viral Infections in Children, Volume I. , 2017, , .		2
210	Ebola and Marburg virus vaccines. <i>Virus Genes</i> , 2017, 53, 501-515.	0.7	70
211	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e280-e292.	4.6	69
212	Reverse Genetics Systems for Filoviruses. <i>Methods in Molecular Biology</i> , 2017, 1602, 159-170.	0.4	6
213	Voluntary vaccination: the pandemic effect. <i>Legal Studies</i> , 2017, 37, 279-304.	0.3	16
214	Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV. <i>Human Gene Therapy Clinical Development</i> , 2017, 28, 108-115.	3.2	38

#	ARTICLE	IF	CITATIONS
215	Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. <i>Vaccine</i> , 2017, 35, 4461-4464.	1.7	28
216	Safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 854-866.	4.6	105
217	Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. <i>Nature Communications</i> , 2017, 8, 15327.	5.8	61
218	Diagnostic preparedness for infectious disease outbreaks. <i>Lancet</i> , The, 2017, 390, 2211-2214.	6.3	53
219	Ancient oncogenesis, infection and human evolution. <i>Evolutionary Applications</i> , 2017, 10, 949-964.	1.5	15
220	Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 115-137.	0.7	3
221	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2017, 215, 1789-1798.	1.9	65
222	Giving voice to African thought in medical research ethics. <i>Theoretical Medicine and Bioethics</i> , 2017, 38, 101-110.	0.4	25
223	Closer than ever to an Ebola virus vaccine. <i>Expert Review of Vaccines</i> , 2017, 16, 401-402.	2.0	5
224	Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea. <i>Vaccine</i> , 2017, 35, 2569-2574.	1.7	10
225	Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara Vectored Ebola Vaccines at 1 Year. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1075.	3.8	67
226	Biochemical testing in a laboratory tent and semi-intensive care of Ebola patients on-site in a remote part of Guinea: a paradigm shift based on a bleach-sensitive point-of-care device. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1881-1890.	1.4	5
227	Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 621-628.	6.3	168
228	Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. <i>Lancet</i> , The, 2017, 389, 578-580.	6.3	3
229	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). <i>Lancet</i> , The, 2017, 389, 505-518.	6.3	837
230	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. <i>The Lancet Global Health</i> , 2017, 5, e324-e334.	2.9	85
231	First Ebola virus vaccine to protect human beings?. <i>Lancet</i> , The, 2017, 389, 479-480.	6.3	9
232	A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 266-270.	1.4	51

#	ARTICLE	IF	CITATIONS
233	Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone. <i>Vaccine</i> , 2017, 35, 544-551.	1.7	21
234	Ebola in great apes – current knowledge, possibilities for vaccination, and implications for conservation and human health. <i>Mammal Review</i> , 2017, 47, 98-111.	2.2	40
235	The Pathogenesis of Ebola Virus Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 387-418.	9.6	266
236	Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review. <i>ILAR Journal</i> , 2017, 58, 343-358.	1.8	171
237	Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane. <i>Expert Review of Vaccines</i> , 2017, 16, 1241-1252.	2.0	43
238	An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1224-1225.	4.6	4
239	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	13.9	199
240	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 <sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.2	33
241	Ethical Considerations in Microbial Therapeutic Clinical Trials. <i>New Bioethics</i> , 2017, 23, 210-218.	0.5	7
242	Pandemic Risk Modelling. , 2017, , 463-495.		2
243	Field-Effect Transistor Biosensor for Rapid Detection of Ebola Antigen. <i>Scientific Reports</i> , 2017, 7, 10974.	1.6	112
244	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. <i>Scientific Reports</i> , 2017, 7, 7284.	1.6	13
245	Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey. <i>Vaccine</i> , 2017, 35, 6915-6923.	1.7	31
246	Open-label phase I clinical trial of Ad5-EBOV in Africans in China. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2078-2085.	1.4	28
247	How many people must die from pandemics before the world learns?. <i>Global Challenges</i> , 2017, 1, 30-32.	1.8	2
248	The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK. <i>Vaccine</i> , 2017, 35, 5081-5088.	1.7	67
249	The Palgrave Handbook of Unconventional Risk Transfer. , 2017, , .		4
250	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. <i>Drugs</i> , 2017, 77, 1935-1966.	4.9	156

#	ARTICLE	IF	CITATIONS
251	Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. <i>Journal of Critical Care</i> , 2017, 42, 366-372.	1.0	23
252	Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1276-1284.	4.6	79
253	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. <i>Scientific Reports</i> , 2017, 7, 4099.	1.6	11
254	Development of respiratory syncytial virus (RSV) vaccines for infants. <i>Journal of Infection</i> , 2017, 74, S143-S146.	1.7	24
255	Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. <i>Vaccine</i> , 2017, 35, 4465-4469.	1.7	44
256	Considerations for Use of Investigational Drugs in Public Health Emergencies. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 146-152.	0.8	7
257	Clinical Management of Ebola Virus Disease Patients in Low-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 93-113.	0.7	5
258	Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. <i>Reviews in Medical Virology</i> , 2017, 27, e1917.	3.9	19
259	Ebola: Anatomy of an Epidemic. <i>Annual Review of Medicine</i> , 2017, 68, 359-370.	5.0	44
260	Viral Hemorrhagic Fevers. , 2017, , 1110-1118.e2.		0
261	Ebola vaccines in clinical trial: The promising candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 153-168.	1.4	48
262	Ebola Vaccination Using a DNA Vaccine Coated on PLGA-PLL/PLGA Nanoparticles Administered Using a Microneedle Patch. <i>Advanced Healthcare Materials</i> , 2017, 6, 1600750.	3.9	92
263	Essential medicines for universal health coverage. <i>Lancet</i> , The, 2017, 389, 403-476.	6.3	366
264	Multivalent and Multipathogen Viral Vector Vaccines. <i>Vaccine Journal</i> , 2017, 24, .	3.2	80
265	Toward an Effective Ebola Virus Vaccine. <i>Annual Review of Medicine</i> , 2017, 68, 371-386.	5.0	29
266	The isolation and improvement of industrially important microorganisms. , 2017, , 75-211.		3
267	Ebola virus disease: An update on current prevention and management strategies. <i>Journal of Clinical Virology</i> , 2017, 86, 5-13.	1.6	25
268	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	4

#	ARTICLE	IF	CITATIONS
270	Psychiatric Aspects of Medical-Surgical Disaster Care. , 0, , 124-139.		0
271	Ebola: The Plague of 2014/2015. , 0, , 1-31.		0
272	In silico-based vaccine design against Ebola virus glycoprotein. Advances and Applications in Bioinformatics and Chemistry, 2017, Volume 10, 11-28.	1.6	55
273	Ebola Virus Disease and Hemorrhagic Fevers. , 2017, , 391-400.		1
274	Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines, 2017, 5, 8.	1.4	44
275	A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. Frontiers in Immunology, 2017, 8, 252.	2.2	23
276	Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4. Frontiers in Microbiology, 2017, 8, 1571.	1.5	56
277	Ebola and Other Viral Hemorrhagic Fevers. , 2017, , 396-409.		2
278	Modeling the Ebola zoonotic dynamics: Interplay between enviroclimatic factors and bat ecology. PLoS ONE, 2017, 12, e0179559.	1.1	24
279	Fighting Ebola: A Window for Vaccine Re-evaluation?. PLoS Pathogens, 2017, 13, e1006037.	2.1	13
280	Bolstering Community Cooperation in Ebola Resurgence Protocols: Combining Field Blood Draw and Point-of-Care Diagnosis. PLoS Medicine, 2017, 14, e1002227.	3.9	14
281	Safety and immunogenicity of rVSV-G-ZEBOV-GP Ebola vaccine in adults and children in Lambaré, Gabon: A phase I randomised trial. PLoS Medicine, 2017, 14, e1002402.	3.9	57
282	Using simulation to aid trial design: Ring-vaccination trials. PLoS Neglected Tropical Diseases, 2017, 11, e0005470.	1.3	25
283	The public health value of vaccines beyond efficacy: methods, measures and outcomes. BMC Medicine, 2017, 15, 138.	2.3	63
284	Simulations for designing and interpreting intervention trials in infectious diseases. BMC Medicine, 2017, 15, 223.	2.3	64
285	Nubia's mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola. Reproductive Health, 2017, 14, 157.	1.2	16
286	Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reproductive Health, 2017, 14, 172.	1.2	69
287	Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. Journal of Clinical Investigation, 2017, 127, 1338-1352.	3.9	188



#	ARTICLE	IF	CITATIONS
288	Replication-Competent Viral Vectors for Vaccine Delivery. , 2017, , 25-63.		1
289	Lessons learned from Ebola Vaccine R&D during a public health emergency. Human Vaccines and Immunotherapeutics, 2018, 14, 2114-2115.	1.4	16
290	The case for ring vaccinations with special consideration of oral cholera vaccines. Human Vaccines and Immunotherapeutics, 2018, 14, 2069-2074.	1.4	9
292	Immune barriers of Ebola virus infection. Current Opinion in Virology, 2018, 28, 152-160.	2.6	25
293	Measles-derived vaccines to prevent emerging viral diseases. Microbes and Infection, 2018, 20, 493-500.	1.0	44
294	Ebola could be eradicated through voluntary vaccination. Royal Society Open Science, 2018, 5, 171591.	1.1	29
295	Post-exposure treatments for Ebola and Marburg virus infections. Nature Reviews Drug Discovery, 2018, 17, 413-434.	21.5	104
296	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. Scientific Reports, 2018, 8, 864.	1.6	43
297	New advances in CNS immunity against viral infection. Current Opinion in Virology, 2018, 28, 116-126.	2.6	35
298	A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Research, 2018, 150, 30-38.	1.9	68
299	HLA variation and disease. Nature Reviews Immunology, 2018, 18, 325-339.	10.6	487
300	A Serological Point-of-Care Test for the Detection of IgG Antibodies against Ebola Virus in Human Survivors. ACS Nano, 2018, 12, 63-73.	7.3	163
301	Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein. Antiviral Research, 2018, 155, 1-11.	1.9	18
302	Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. Emerging Microbes and Infections, 2018, 7, 1-15.	3.0	32
304	Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. Clinical Infectious Diseases, 2018, 66, 1140-1146.	2.9	17
305	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. Microbiology Spectrum, 2018, 6, .	1.2	6
306	Questionable efficacy of the rVSV-ZEBOV Ebola vaccine â€œ Authors' reply. Lancet, The, 2018, 391, 1021-1022.	6.3	8
307	Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. Vaccine, 2018, 36, 3090-3100.	1.7	35

#	ARTICLE	IF	CITATIONS
308	Forecasting Ebola with a regression transmission model. <i>Epidemics</i> , 2018, 22, 50-55.	1.5	24
309	The Ebola clinical trials: a precedent for research ethics in disasters. <i>Journal of Medical Ethics</i> , 2018, 44, 3-8.	1.0	47
310	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028902.	2.3	31
311	Technologies for Making New Vaccines. , 2018, , 1283-1304.e7.		5
312	Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring. <i>Computational Biology and Chemistry</i> , 2018, 72, 170-180.	1.1	45
313	Disaster Preparedness: Biological Threats and Treatment Options. <i>Pharmacotherapy</i> , 2018, 38, 217-234.	1.2	30
314	Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. <i>Journal of Virology</i> , 2018, 92, .	1.5	21
315	Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. <i>Journal of Virology</i> , 2018, 92, .	1.5	34
316	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	1.4	35
317	Ebola virus disease: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. <i>Journal of Critical Care</i> , 2018, 43, 352-355.	1.0	10
318	Aspects of disaster research ethics applicable to other contexts. <i>Journal of Medical Ethics</i> , 2018, 44, 9-10.	1.0	3
319	Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.	1.7	43
320	Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. <i>Human Gene Therapy</i> , 2018, 29, 87-95.	1.4	7
321	Establishing and Utilizing Strategic Partnerships for Vaccine-Preventable Diseases. <i>Infectious Diseases in Clinical Practice</i> , 2018, 26, 252-257.	0.1	1
322	Searching for Superspreaders: Identifying Epidemic Patterns Associated with Superspreading Events in Stochastic Models. <i>Association for Women in Mathematics Series</i> , 2018, , 1-29.	0.1	6
323	Planning for large epidemics and pandemics. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 316-324.	1.3	29
324	Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. <i>Human Gene Therapy Clinical Development</i> , 2018, 29, 226-232.	3.2	11
325	Self-Replicating RNA Viruses for RNA Therapeutics. <i>Molecules</i> , 2018, 23, 3310.	1.7	49

#	ARTICLE	IF	CITATIONS
326	Implementation research: new imperatives and opportunities in global health. <i>Lancet</i> , The, 2018, 392, 2214-2228.	6.3	308
327	Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006628.	1.3	53
328	Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. <i>PLoS ONE</i> , 2018, 13, e0202753.	1.1	39
329	Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program. <i>Expert Review of Vaccines</i> , 2018, 17, 913-923.	2.0	9
330	A framework for research on vaccine effectiveness. <i>Vaccine</i> , 2018, 36, 7286-7293.	1.7	30
332	Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola. <i>Journal of Infectious Diseases</i> , 2018, 217, S16-S23.	1.9	19
333	Fresh approaches to vaccine development. <i>EMBO Reports</i> , 2018, 19, .	2.0	3
334	Current research for a vaccine against Lassa hemorrhagic fever virus. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2519-2527.	2.0	47
335	Letters to the editor. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2018, 48, 284-286.	0.2	0
336	Rapid Establishment of a Cold Chain Capacity of $\leq 60^{\circ}\text{C}$ or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone. <i>Journal of Infectious Diseases</i> , 2018, 217, S48-S55.	1.9	34
337	Ebola: Lessons on Vaccine Development. <i>Annual Review of Microbiology</i> , 2018, 72, 423-446.	2.9	51
338	Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak. <i>Viruses</i> , 2018, 10, 439.	1.5	6
339	A humanitarian response to the West African Ebola virus disease outbreak. <i>Journal of International Humanitarian Action</i> , 2018, 3, .	0.7	6
340	The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV $\Delta$ g-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. <i>Journal of Infectious Diseases</i> , 2018, 217, S6-S15.	1.9	66
341	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. <i>Annals of Applied Statistics</i> , 2018, 12, 330-347.	0.5	6
342	Contagion and Public Health in Switzerland: Wilhelm Ost, MD (1853 $\leq$ 1922), Polizeiarzt. <i>American Journal of Public Health</i> , 2018, 108, 629-630.	1.5	0
343	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2107-2113.	1.4	107
344	Optimization of Isothiazolo[4,3- <i>b</i> ]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6178-6192.	2.9	36

#	ARTICLE	IF	CITATIONS
345	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S612-S626.	1.9	146
346	A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. <i>Nature Communications</i> , 2018, 9, 3067.	5.8	65
347	A comparative computational genomics of Ebola Virus Disease strains: In-silico Insight for Ebola control. <i>Informatics in Medicine Unlocked</i> , 2018, 12, 106-119.	1.9	15
348	Analysis of CD8 <sup>+</sup> T cell response during the 2013–2016 Ebola epidemic in West Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7578-E7586.	3.3	55
349	Applications of gold nanoparticles in virus detection. <i>Theranostics</i> , 2018, 8, 1985-2017.	4.6	256
350	Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. <i>Scientific Reports</i> , 2018, 8, 11193.	1.6	26
351	Qualitative Profiling of the Humoral Immune Response Elicited by rVSV-Î”G-EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays. <i>Cell Reports</i> , 2018, 24, 1050-1059.e5.	2.9	11
352	A VSV-based Zika virus vaccine protects mice from lethal challenge. <i>Scientific Reports</i> , 2018, 8, 11043.	1.6	63
353	Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man. <i>Vaccines</i> , 2018, 6, 43.	2.1	24
354	Correlates of vaccine-induced protective immunity against Ebola virus disease. <i>Seminars in Immunology</i> , 2018, 39, 65-72.	2.7	44
355	Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. <i>Molecular Therapy - Oncolytics</i> , 2018, 10, 1-13.	2.0	7
356	Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin. <i>Vaccines</i> , 2018, 6, 16.	2.1	2
357	Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. <i>Cell Reports</i> , 2018, 24, 1802-1815.e5.	2.9	64
358	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	5.1	182
360	New Vaccine Technologies to Combat Outbreak Situations. <i>Frontiers in Immunology</i> , 2018, 9, 1963.	2.2	437
361	DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. <i>Scientific Reports</i> , 2018, 8, 12459.	1.6	21
362	Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. <i>Viral Immunology</i> , 2018, 31, 500-512.	0.6	3
363	Development of Gene-Based Vectors for Immunization. , 2018, , 1305-1319.e8.		3

#	ARTICLE	IF	CITATIONS
364	Regulation of Vaccines in Low- and Middle-Income Countries. , 2018, , 1573-1583.e1.		2
365	Disabling of lymphocyte immune response by Ebola virus. PLoS Pathogens, 2018, 14, e1006932.	2.1	23
366	Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge. Journal of Infectious Diseases, 2018, 218, S545-S552.	1.9	16
367	Ebolaviruses: New roles for old proteins. PLoS Neglected Tropical Diseases, 2018, 12, e0006349.	1.3	33
368	Ebola Vaccines. , 2018, , 276-287.e5.		0
369	Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions. Clinical Infectious Diseases, 2019, 68, 330-333.	2.9	39
372	Ebola vaccine innovation: a case study of pseudoscapes in global health. Critical Public Health, 2019, 29, 401-412.	1.4	11
373	Nursesâ€™ experiences of health concerns, teamwork, leadership and knowledge transfer during an Ebola outbreak in West Africa. Nursing Open, 2019, 6, 824-833.	1.1	15
374	Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Human Vaccines and Immunotherapeutics, 2019, 15, 2269-2285.	1.4	58
375	Immunogenicity, Lot Consistency, and Extended Safety of rVSVÎ”G-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. Journal of Infectious Diseases, 2019, 220, 1127-1135.	1.9	42
376	Evaluating Temperature Sensitivity of Vesicular Stomatitis Virusâ€“Based Vaccines. Emerging Infectious Diseases, 2019, 25, 1563-1566.	2.0	4
377	Polyphenylene carboxymethylene (PPCM) in vitro antiviral efficacy against Ebola virus in the context of a sexually transmitted infection. Antiviral Research, 2019, 170, 104567.	1.9	8
378	Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 2019, 11, .	5.8	41
379	Impacts of environmental and socio-economic factors on emergence and epidemic potential of Ebola in Africa. Nature Communications, 2019, 10, 4531.	5.8	63
380	Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. Microorganisms, 2019, 7, 402.	1.6	16
381	Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea. Vaccine, 2019, 37, 7165-7170.	1.7	11
382	Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Human Vaccines and Immunotherapeutics, 2019, 15, 2359-2377.	1.4	31
383	Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. EBioMedicine, 2019, 49, 223-231.	2.7	34

#	ARTICLE	IF	CITATIONS
384	A review of Lassa fever vaccine candidates. <i>Current Opinion in Virology</i> , 2019, 37, 105-111.	2.6	31
385	Ebola Virus: Pathogenesis and Countermeasure Development. <i>Annual Review of Virology</i> , 2019, 6, 435-458.	3.0	50
386	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	1.9	59
388	Responding to the Ebola virus disease outbreak in DR Congo: when will we learn from Sierra Leone?. <i>Lancet, The</i> , 2019, 393, 2647-2650.	6.3	21
389	Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection. <i>MBio</i> , 2019, 10, .	1.8	33
390	Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. <i>Emerging Infectious Diseases</i> , 2019, 25, 1144-1152.	2.0	41
391	Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. <i>Nature Microbiology</i> , 2019, 4, 1558-1570.	5.9	44
392	The Impact of Various Promotional Activities on Ebola Prevention Behaviors and Psychosocial Factors Predicting Ebola Prevention Behaviors in the Gambia Evaluation of Ebola Prevention Promotions. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2020.	1.2	21
393	Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach. <i>Microbial Pathogenesis</i> , 2019, 132, 243-253.	1.3	57
394	Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. <i>Viruses</i> , 2019, 11, 326.	1.5	478
395	rVSV <sup>ΔG</sup> -ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine: X</i> , 2019, 1, 100009.	0.9	61
396	Ebola vaccination in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10178-10183.	3.3	38
397	Vaccine platforms for the prevention of Lassa fever. <i>Immunology Letters</i> , 2019, 215, 1-11.	1.1	43
398	Retrospective versus real-time Ebola virus sequencing. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 567-568.	4.6	3
399	Challenges and perspectives on the use of mobile laboratories during outbreaks and their use for vaccine evaluation. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2264-2268.	1.4	8
400	Intradermal SynCon <sup>®</sup> Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. <i>Journal of Infectious Diseases</i> , 2019, 220, 400-410.	1.9	91
401	RNA Viruses as Tools in Gene Therapy and Vaccine Development. <i>Genes</i> , 2019, 10, 189.	1.0	51
402	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epitope vaccine. <i>PLoS Pathogens</i> , 2019, 15, e1007564.	2.1	20

#	ARTICLE	IF	CITATIONS
403	Disentangling What We Know About Microbes and Mental Health. <i>Frontiers in Endocrinology</i> , 2019, 10, 81.	1.5	16
404	Development and characterization of a Zaire Ebola (ZEBOV) specific IgM ELISA. <i>Journal of Immunological Methods</i> , 2019, 468, 29-34.	0.6	3
405	Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. <i>Frontiers in Immunology</i> , 2019, 10, 372.	2.2	57
406	Outbreak science: recent progress in the detection and response to outbreaks of infectious diseases. <i>Clinical Medicine</i> , 2019, 19, 140-144.	0.8	36
407	NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
408	A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. <i>Npj Vaccines</i> , 2019, 4, 8.	2.9	30
409	Process mapping of vaccines: Understanding the limitations in current response to emerging epidemic threats. <i>Vaccine</i> , 2019, 37, 2415-2421.	1.7	13
410	Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic. <i>American Journal of Epidemiology</i> , 2019, 188, 1319-1327.	1.6	11
411	Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. <i>Health Security</i> , 2019, 17, 46-53.	0.9	5
412	Vaccine Development for Nipah Virus Infection in Pigs. <i>Frontiers in Veterinary Science</i> , 2019, 6, 16.	0.9	19
413	Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR. <i>SAR and QSAR in Environmental Research</i> , 2019, 30, 161-180.	1.0	26
414	Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 308-316.	4.6	36
415	Ebola™s Assault on Women, Children, and Family Reproduction: An Introduction to the Issues. <i>Global Maternal and Child Health</i> , 2019, , 3-9.	0.1	3
416	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0
417	Efficacy of Isolation as a Control Strategy for Ebola Outbreaks in Combination with Vaccination. <i>Biophysical Reviews and Letters</i> , 2019, 14, 115-139.	0.9	0
418	Marburg virus pathogenesis – differences and similarities in humans and animal models. <i>Virology Journal</i> , 2019, 16, 165.	1.4	44
419	Ebola vaccine trials: progress in vaccine safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2019, 18, 1229-1242.	2.0	61
420	Monoclonal Antibody Therapy for Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2019, 381, 2365-2366.	13.9	52

#	ARTICLE	IF	CITATIONS
421	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebola virus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	2.9	7
422	Vaccination strategies to control Ebola epidemics in the context of variable household inaccessibility levels. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007814.	1.3	15
423	Maternal and Infant Death and the rVSV-ZEBOV Vaccine Through Three Recent Ebola Virus Epidemics-West Africa, DRC %quateur and DRC Kivu: 4 Years of Excluding Pregnant and Lactating Women and Their Infants from Immunization. <i>Current Tropical Medicine Reports</i> , 2019, 6, 213-222.	1.6	17
424	A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice. <i>Viruses</i> , 2019, 11, 1149.	1.5	11
425	Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. <i>Trends in Microbiology</i> , 2019, 27, 8-16.	3.5	32
426	Current Ebola Virus Vaccine Progress. <i>BioDrugs</i> , 2019, 33, 9-14.	2.2	32
427	Detectable Vesicular Stomatitis Virus (VSV)â€™Specific Humoral and Cellular Immune Responses Following VSVâ€™Ebola Virus Vaccination in Humans. <i>Journal of Infectious Diseases</i> , 2019, 219, 556-561.	1.9	29
428	Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0006919.	1.3	71
429	PREVAIL I Cluster Vaccination Study With rVSVÎ”G-ZEBOV-GP as Part of a Public Health Response in Liberia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1634-1641.	1.9	12
430	Identification of novel HLA-A11-restricted T-cell epitopes in the Ebola virus nucleoprotein. <i>Microbes and Infection</i> , 2019, 21, 56-62.	1.0	6
431	Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. <i>Vaccine</i> , 2019, 37, 7171-7177.	1.7	22
432	Considerations for use of Ebola vaccine during an emergency response. <i>Vaccine</i> , 2019, 37, 7190-7200.	1.7	23
433	Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. <i>Vaccine</i> , 2019, 37, 7178-7182.	1.7	7
434	The induction and characterization of monoclonal antibodies specific to GP of Ebola virus. <i>Journal of Medical Virology</i> , 2020, 92, 996-1006.	2.5	1
435	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879.	2.9	17
436	Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.	3.0	79
437	Contemporary Understanding of Ebola and Zika Virus in Pregnancy. <i>Clinics in Perinatology</i> , 2020, 47, 835-846.	0.8	3
438	Immune correlates analysis using vaccinees from test negative designs. <i>Biostatistics</i> , 2022, 23, 507-521.	0.9	5



#	ARTICLE	IF	CITATIONS
439	Assessing the Safety of COVID-19 Vaccines: A Primer. <i>Drug Safety</i> , 2020, 43, 1205-1210.	1.4	34
440	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.	1.6	12
441	Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. <i>Viruses</i> , 2020, 12, 1324.	1.5	35
442	Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity. <i>Frontiers in Immunology</i> , 2020, 11, 586595.	2.2	8
443	Ebola, COVID-19, and emerging infectious disease: lessons learned and future preparedness. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 416-422.	1.3	9
444	Self-Amplifying RNA Viruses as RNA Vaccines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5130.	1.8	54
445	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , 2020, 28, 465-474.e4.	5.1	156
446	Key questions for modelling COVID-19 exit strategies. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2020, 287, 20201405.	1.2	106
447	Estimating the protective effect of case isolation with transmission tree reconstruction during the Ebola outbreak in Nigeria, 2014. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20200498.	1.5	4
448	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020, 20, 615-632.	10.6	806
449	Environmental Risk Assessment for rVSV <sup>Δ</sup> G-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease. <i>Vaccines</i> , 2020, 8, 779.	2.1	10
450	Viral Sovereignty, Technology Transfer, and the Changing Global System for Sharing Pathogens for Public Health Research. , 2020, , 1-28.		0
451	Comparing EM Approaches for Studying Filoviral Glycoproteins. <i>Microscopy and Microanalysis</i> , 2020, 26, 2736-2738.	0.2	0
452	Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	41
453	Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. <i>Biomedical Journal</i> , 2020, 43, 375-387.	1.4	24
454	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. <i>Vaccines</i> , 2020, 8, 241.	2.1	12
455	Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	10
456	Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection. <i>Frontiers in Microbiology</i> , 2020, 11, 304.	1.5	1

#	ARTICLE	IF	CITATIONS
457	Pregnancy Outcomes among Women Receiving rVSV <sup>Î</sup> -ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola. <i>Emerging Infectious Diseases</i> , 2020, 26, 541-548.	2.0	26
458	Uganda's experience in Ebola virus disease outbreak preparedness, 2018-2019. <i>Globalization and Health</i> , 2020, 16, 24.	2.4	59
459	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.	1.3	20
460	Statistics in Clinical and Observational Vaccine Studies. <i>Springer Series in Pharmaceutical Statistics</i> , 2020, , .	0.0	10
461	Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors. <i>Journal of Virology</i> , 2020, 94, .	1.5	14
462	The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. <i>Expert Review of Vaccines</i> , 2020, 19, 267-277.	2.0	17
463	Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebola virus vaccination. <i>Npj Vaccines</i> , 2020, 5, 32.	2.9	18
464	A tool with many applications: vesicular stomatitis virus in research and medicine. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1187-1201.	1.4	35
465	Controlling timing and location in vaccines. <i>Advanced Drug Delivery Reviews</i> , 2020, 158, 91-115.	6.6	141
466	Safety, immunogenicity and risk-benefit analysis of rVSV-ÎG-ZEBOV-GP (V920) Ebola vaccine in Phase III clinical trials across regions. <i>Future Microbiology</i> , 2020, 15, 85-106.	1.0	23
467	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	18.1	340
468	Human Antibody Repertoire following Ebola Virus Infection and Vaccination. <i>IScience</i> , 2020, 23, 100920.	1.9	8
469	Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. <i>Cell Host and Microbe</i> , 2020, 27, 262-276.e4.	5.1	29
470	Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 455-466.	4.6	22
471	Biomimetic Design of Peptide Neutralizer of Ebola Virus with Molecular Simulation. <i>Langmuir</i> , 2020, 36, 1813-1821.	1.6	16
472	Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-up hydro fixed-bed. <i>Journal of Biotechnology</i> , 2020, 310, 32-39.	1.9	24
473	A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. <i>MBio</i> , 2020, 11, .	1.8	34
474	The C-Terminal Domain of the Sudan Ebolavirus L Protein Is Essential for RNA Binding and Methylation. <i>Journal of Virology</i> , 2020, 94, .	1.5	12

#	ARTICLE	IF	CITATIONS
475	The Plasma Mobile, â€ˆA gift from heavenâ€™™: The impact of health technology transfer on trial perceptions and expectations during the Ebola-Tx Trial, Conakry. PLoS Neglected Tropical Diseases, 2020, 14, e0008206.	1.3	1
476	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clinical Infectious Diseases, 2021, 72, 2035-2041.	2.9	15
477	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 507-516.	4.6	26
478	Vaccine innovation spurred by the long wait for an Ebola virus vaccine. Lancet Infectious Diseases, The, 2021, 21, 440-441.	4.6	10
479	Nanocarrier-based vaccine delivery systems for synthetic peptide vaccines. , 2021, , 509-535.		2
480	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12.	26.7	37
481	Ebola virus antibody decayâ€™stimulation in a high proportion of survivors. Nature, 2021, 590, 468-472.	13.7	30
482	Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production. Vaccines, 2021, 9, 59.	2.1	1
483	Ebolavirus and Other Filoviruses. , 2021, , .		0
485	COVID-19 in comparison with other emerging viral diseases: risk of geographic spread via travel. Tropical Diseases, Travel Medicine and Vaccines, 2021, 7, 3.	0.9	50
486	Ocular manifestations of emerging viral diseases. Eye, 2021, 35, 1117-1139.	1.1	26
487	Philanthrocapitalism and Global Health. , 2021, , 416-428.		0
488	Teaching Global Health Ethics. , 2021, , 459-469.		0
489	Responsibility for Global Health. , 2021, , 136-145.		1
490	Global Health Research. , 2021, , 370-382.		0
491	Justice and Global Health: Planetary Considerations. , 2021, , 316-325.		0
492	The International Arms Trade and Global Health. , 2021, , 182-194.		0
493	Allocating Resources in Humanitarian Medicine. , 2021, , 195-206.		0

#	ARTICLE	IF	CITATIONS
494	Animals, the Environment, and Global Health. , 2021, , 304-315.		1
497	Giving Voice to African Thought in Medical Research Ethics. , 2021, , 339-344.		0
498	Morbid Symptoms, Organic Crises, and Enclosures of the Commons. , 2021, , 242-255.		2
499	Geopolitics, Disease, and Inequalities in Emerging Economies. , 2021, , 221-229.		0
500	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013â€“16 West Africa epidemic. Nature Communications, 2021, 12, 1153.	5.8	10
501	State of Global Health in a Radically Unequal World. , 2021, , 15-27.		1
502	Strengthening the Global Response to Infectious Disease Threats in the Twenty-First Century, with a COVID-19 Epilogue. , 2021, , 51-75.		1
503	Is There a Need for Global Health Ethics?. , 2021, , 98-109.		0
504	Development Assistance for Health. , 2021, , 207-220.		1
505	Health Systems and Health and Healthcare Reform. , 2021, , 86-97.		1
506	Bioethics and Global Child Health. , 2021, , 146-157.		0
507	Neoliberalism, Power Relations, Ethics, and Global Health. , 2021, , 230-241.		1
508	The Health Impact Fund. , 2021, , 394-405.		1
509	Societal Determinants and Determination of Health. , 2021, , 28-50.		1
510	Big Data and Artificial Intelligence for Global Health. , 2021, , 429-439.		3
511	The 100 Top-cited Studies on Ebola: A Bibliometric Analysis. Electronic Journal of General Medicine, 2021, 18, em276.	0.3	5
513	Evaluating Global Health Impact and Increasing Access to Essential Medicines. , 2021, , 406-415.		1
514	Trade and Health. , 2021, , 158-169.		0

#	ARTICLE	IF	CITATIONS
515	Global Health Governance for Developing Sustainability. , 2021, , 440-449.		1
516	Interphilosophies Dialogue. , 2021, , 345-357.		0
517	Estimation of the correlates of protection of the rVSV <sup>GP</sup> -ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. Lancet Microbe, The, 2021, 2, e70-e78.	3.4	19
518	The Human Right to Health. , 2021, , 110-121.		0
519	Global Health and Ethical Transculturalism. , 2021, , 326-338.		3
520	Teaching Global Health Ethics. , 2021, , 450-458.		1
521	Justice and Research in Developing Countries. , 2021, , 383-393.		0
522	Challenging the Global Extractive Order. , 2021, , 256-268.		1
523	International Human Rights Law and the Social Determinants of Health. , 2021, , 122-135.		1
524	Viral Vectors for COVID-19 Vaccine Development. Viruses, 2021, 13, 317.	1.5	65
526	Debt, Structural Adjustment, and Health. , 2021, , 170-181.		1
527	Mass Migration and Health in the Anthropocene Epoch. , 2021, , 293-303.		1
528	Gender Equality in Science, Medicine, and Global Health. , 2021, , 76-85.		0
529	Reframing Global Health Ethics Using Ecological, Indigenous, and Regenerative Lenses. , 2021, , 358-369.		0
530	Ecological Ethics, Planetary Sustainability, and Global Health. , 2021, , 281-292.		2
531	Toward a New Common Sense. , 2021, , 470-477.		2
532	The Environment, Ethics, and Health. , 2021, , 269-280.		0
533	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. Frontiers in Immunology, 2020, 11, 599568.	2.2	16

#	ARTICLE	IF	CITATIONS
534	The potential neurological effect of the COVID-19 vaccines: A review. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 3-12.	1.0	85
535	Chemogenetic ON and OFF switches for RNA virus replication. <i>Nature Communications</i> , 2021, 12, 1362.	5.8	6
536	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021, 22, 224.	0.7	8
537	Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo. <i>Nature Medicine</i> , 2021, 27, 710-716.	15.2	35
538	Increasing efficacy of contact-tracing applications by user referrals and stricter quarantining. <i>PLoS ONE</i> , 2021, 16, e0250435.	1.1	3
539	Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	4
540	Ebola, Dengue, Chikungunya, and Zika Infections in Neonates and Infants. <i>Clinics in Perinatology</i> , 2021, 48, 311-329.	0.8	10
541	Antibody responses to filovirus infections in humans: protective or not?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e348-e355.	4.6	3
542	A hybrid simulation model to study the impact of combined interventions on Ebola epidemic. <i>PLoS ONE</i> , 2021, 16, e0254044.	1.1	5
543	Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
544	Vaccine Development Throughout History. <i>Cureus</i> , 2021, 13, e16635.	0.2	19
545	The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. <i>Life</i> , 2021, 11, 734.	1.1	34
547	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
548	Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 33-41.	0.6	8
549	SARS-CoV-2 Variants and Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 179-186.	13.9	322
550	Ebola virus disease: current vaccine solutions. <i>Current Opinion in Immunology</i> , 2021, 71, 27-33.	2.4	52
551	Vesicular Stomatitis Virus Chimeras Expressing the Oropouche Virus Glycoproteins Elicit Protective Immune Responses in Mice. <i>MBio</i> , 2021, 12, e0046321.	1.8	9
552	Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals. <i>International Journal of Production Economics</i> , 2021, 239, 108193.	5.1	130

#	ARTICLE	IF	CITATIONS
553	A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. <i>Journal of Virology</i> , 2021, 95, e0059221.	1.5	11
554	Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , 2021, 8, 651658.	1.2	38
555	Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20â€™22 April 2021. <i>Vaccine</i> , 2021, 39, 7223-7229.	1.7	8
556	Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention. , 2021, , 159-183.		0
557	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
558	Accelerating Vaccine Development During the 2013â€™2016 West African Ebola Virus Disease Outbreak. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 229-261.	0.7	14
559	Global Convergent Translational Science for Neuro-involvement in Ebola Viral Disease: Lessons Learned from Neuro-AIDS. , 2017, , 751-777.		1
560	Types of Disasters. , 2020, , 85-197.		5
561	Real-Time Assessment of the International Spreading Risk Associated with the 2014 West African Ebola Outbreak. , 2016, , 39-56.		5
563	Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs. <i>Journal of General Virology</i> , 2018, 99, 866-879.	1.3	5
567	West Africa 2013: Re-examining Ebola. , 0, , 1-37.		1
568	Viral Agents of Human Disease: Biosafety Concerns. , 0, , 187-220.		1
569	Lassa virus diversity and feasibility for universal prophylactic vaccine. <i>F1000Research</i> , 2019, 8, 134.	0.8	29
570	Public acceptance of a hypothetical Ebola virus vaccine in Aceh, Indonesia: A hospital-based survey. <i>Asian Pacific Journal of Tropical Disease</i> , 2017, 7, 193-198.	0.5	6
571	Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial. <i>PLoS Medicine</i> , 2016, 13, e1002120.	3.9	38
572	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535.	3.9	108
573	Transforming Clinical Data into Actionable Prognosis Models: Machine-Learning Framework and Field-Deployable App to Predict Outcome of Ebola Patients. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004549.	1.3	49
574	Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004802.	1.3	8

#	ARTICLE	IF	CITATIONS
575	Minimally Symptomatic Infection in an Ebola "Hotspot": A Cross-Sectional Serosurvey. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005087.	1.3	49
576	New Perspectives on Ebola Virus Evolution. <i>PLoS ONE</i> , 2016, 11, e0160410.	1.1	6
577	National Survey Indicates that Individual Vaccination Decisions Respond Positively to Community Vaccination Rates. <i>PLoS ONE</i> , 2016, 11, e0166858.	1.1	13
578	Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey. <i>PLoS ONE</i> , 2017, 12, e0173148.	1.1	7
579	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	1.1	64
580	Ebolavirus Evolution: Past and Present. <i>PLoS Pathogens</i> , 2015, 11, e1005221.	2.1	58
581	Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. <i>PLoS Pathogens</i> , 2017, 13, e1006397.	2.1	58
583	Ebola Virus Disease " Sierra Leone and Guinea, August 2015. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 981-984.	9.0	15
584	Implementing an Ebola Vaccine Study " Sierra Leone. <i>MMWR Supplements</i> , 2016, 65, 98-106.	15.3	60
585	Viruses Causing Hemorrhagic Fever. Safety Laboratory Procedures. <i>The Open Virology Journal</i> , 2016, 10, 1-9.	1.8	7
586	Mobile diagnostics in outbreak response, not only for Ebola: a blueprint for a modular and robust field laboratory. <i>Eurosurveillance</i> , 2015, 20, .	3.9	45
587	Duration of Ebola virus RNA persistence in semen of survivors: population-level estimates and projections. <i>Eurosurveillance</i> , 2015, 20, 30083.	3.9	25
588	Field investigation with real-time virus genetic characterisation support of a cluster of Ebola virus disease cases in DubrÅ©ka, Guinea, April to June 2015. <i>Eurosurveillance</i> , 2018, 23, .	3.9	11
589	Virus-Vectored Ebola Vaccines. <i>Acta Naturae</i> , 2017, 9, 4-11.	1.7	24
590	Modeling ebola virus disease transmissions with reservoir in a complex virus life ecology. <i>Mathematical Biosciences and Engineering</i> , 2017, 15, 21-56.	1.0	21
591	The potential impact of a prophylactic vaccine for Ebola in Sierra Leone. <i>Mathematical Biosciences and Engineering</i> , 2017, 15, 337-359.	1.0	19
592	Global asymptotic behavior for mixed vaccination strategy in a delayed epidemic model with interim-immune. <i>Mathematical Biosciences and Engineering</i> , 2020, 17, 3601-3617.	1.0	3
593	The Ebola outbreak of 2014-2015: From coordinated multilateral action to effective disease containment, vaccine development, and beyond. <i>Journal of Global Infectious Diseases</i> , 2015, 7, 127.	0.2	40



#	ARTICLE	IF	CITATIONS
594	Reducing Uncertainty for Acute Febrile Illness in Resource-Limited Settings: The Current Diagnostic Landscape. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1285-1295.	0.6	13
596	Initiating a watch list for Ebola virus antibody escape mutations. PeerJ, 2016, 4, e1674.	0.9	36
597	Exploratory investigation of region level risk factors of Ebola Virus Disease in West Africa. PeerJ, 2018, 6, e5888.	0.9	7
598	Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines, 2021, 9, 1187.	2.1	30
599	VSV-EBOV Induces Temporal and Dose-Dependent Transcriptional Responses in Non-human Primates. Frontiers in Virology, 2021, 1, .	0.7	0
600	Challenges of evaluating and modelling vaccination in emerging infectious diseases. Epidemics, 2021, 37, 100506.	1.5	14
601	Ebola Fever and Advances in the Antiviral Therapies. Journal of Human Virology & Retrovirology, 2015, 2, .	0.1	0
602	70th Anniversary Collection of the Microbiology Society: Journal of General Virology. Journal of General Virology, 2015, 96, 3457-3459.	1.3	1
604	Viren Ã¼berlisten: Globale Virusinfektionen werden beherrschbar â€œ aber neue Gefahren drohen. , 2016, , 101-117.		0
605	Did Neoliberalizing West Africaâ€™s Forests Produce a Vaccine-Resistant Ebola?. , 2016, , 55-68.		0
606	Statistical Considerations in Infectious Disease Randomized Controlled Trials. , 2016, , 303-312.		0
607	Ebola-Fieber und die Epidemie in Westafrika. Der Merkurstab, 2016, 69, 127-133.	0.0	0
610	Arenaviruses. , 0, , 1089-1111.		0
611	Viral Hemorrhagic Fevers. , 0, , 141-150.		0
612	ESCAIDE 2015: an operational scientific conference on infectious diseases for professionals from Europe and beyond. Eurosurveillance, 2016, 21, 30166.	3.9	0
613	Filoviruses. , 0, , 981-1007.		1
614	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. , 0, , 39-52.		0
615	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. , 0, , 53-71.		1

#	ARTICLE	IF	CITATIONS
618	Arboviroses et fiÃvres hÃmorrhagiques : actualitÃs ÃpidÃmiologique et vaccinale. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 1617-1630.	0.0	0
619	Vaccines and Prevention. , 2017, , 25-36.		0
620	Emerging Zoonotic and Vector-Borne Viral Diseases. , 2017, , 125-150.		0
621	Ebola in West Africa: Biosocial and Biomedical Reflections. Boston Studies in the Philosophy and History of Science, 2017, , 143-164.	0.4	0
623	Effectiveness of Ideological and Political Education in Colleges and Universities under the Outbreak of Internet Media. Eurasia Journal of Mathematics, Science and Technology Education, 2017, 13, .	0.7	6
624	Simmering to the End (January 2015âJune 2016). , 2018, , 227-310.		0
625	Ebolaâs Fatal Hemorrhagic Fever from Discovery to Vaccine. Journal of Tropical Diseases, 2018, 06, .	0.1	0
627	Ebola-Impfstoff-Entwicklung: Im Krisenfall schnell, aber mit hohem Sicherheitsanspruch. Deutsches A&#x0308;rzteblatt International, 0, , .	0.6	0
630	Ebola Virus Disease: Progress So Far in the Management of the Disease. , 0, , .		0
631	Global Emerging Pathogens and the (Prescriptive) Role of the World Health Organization. , 2019, , 135-142.		1
632	Ebola Virus Disease - clinical manifestations, management and future therapies. Journal of the Royal Naval Medical Service, 2019, 105, 113-120.	0.0	0
633	Western African Ebola virus epidemic. WikiJournal of Medicine, 2019, 6, .	1.0	2
634	Modeling outbreak data: Analysis of a 2012 Ebola virus disease epidemic in DRC. Biomath, 2019, 8, 1910037.	0.3	1
635	Nipah Virus- A Rapidly Emerging Zoonoses: A Mini Review. National Journal of Health Sciences, 2019, 4, 158-162.	0.1	0
637	Selected Infectious Diseases. , 2020, , 1-20.		0
638	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Current Opinion in Virology, 2021, 51, 179-189.	2.6	7
640	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12.	26.7	0
641	International Congress on Targeting Ebola: 28-29 May 2015, Pasteur Institute, Paris. Journal of Virus Eradication, 2015, 1, 282-3.	0.3	0

#	ARTICLE	IF	CITATIONS
642	Virus-Vectored Ebola Vaccines. <i>Acta Naturae</i> , 2017, 9, 4-11.	1.7	3
643	Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo. <i>Vaccine</i> , 2021, , .	1.7	0
644	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 389.	7.1	21
645	<i>Selected Infectious Diseases.</i> , 2022, , 587-606.		0
646	<i>Filoviruses: modern solutions to life-threatening infections.</i> , 2022, , 369-394.		0
647	The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks. <i>Clinical Trials</i> , 2022, 19, 402-406.	0.7	7
648	Assessment of COVID-19 Vaccine Acceptance and Willingness to Pay by Nigerians. <i>Health</i> , 2022, 14, 137-157.	0.1	2
649	Immunogenicity of rVSV-G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
651	Adherence to COVID-19 Preventive Behaviours: the Implication of Life Orientation and Sociodemographic Factors among Residents in Nigeria. <i>Psychology</i> , 2022, 13, 469-481.	0.3	2
652	Self-replicating vehicles based on negative strand RNA viruses. <i>Cancer Gene Therapy</i> , 2022, , .	2.2	3
653	First laboratory confirmation and sequencing of Zaire ebolavirus in Uganda following two independent introductions of cases from the 10th Ebola Outbreak in the Democratic Republic of the Congo, June 2019. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010205.	1.3	2
654	Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19. <i>Nature Communications</i> , 2022, 13, 1414.	5.8	14
655	Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. <i>Vaccines</i> , 2022, 10, 533.	2.1	5
656	Therapeutic Strategies against Ebola Virus Infection. <i>Viruses</i> , 2022, 14, 579.	1.5	16
657	The road to effective and accessible antibody therapies against Ebola virus. <i>Current Opinion in Virology</i> , 2022, 54, 101210.	2.6	7
660	Neutralizing Antibody Titer Test of Ebola Recombinant Protein Vaccine and Gene Vector Vaccine pVR-GP-FC. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 721-728.	0.2	1
661	Immunization of Healthcare Personnel: A Continuing Issue. <i>Vaccine: X</i> , 2022, 11, 100169.	0.9	0
662	A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases. <i>Epidemiologic Reviews</i> , 2022, 44, 29-54.	1.3	1

#	ARTICLE	IF	CITATIONS
663	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28
665	Developing Students' Intuition on the Impact of Correlated Outcomes. <i>Journal of Statistics and Data Science Education</i> , 0, , 1-11.	0.9	0
666	Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng. <i>Journal of Ginseng Research</i> , 2023, 47, 123-132.	3.0	5
667	Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols. <i>PLoS ONE</i> , 2022, 17, e0270968.	1.1	3
668	Applications of self-replicating RNA. <i>International Review of Cell and Molecular Biology</i> , 2022, , .	1.6	3
669	A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. <i>Clinical Trials</i> , 2022, 19, 647-654.	0.7	10
670	Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	6
671	Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. <i>Vaccines</i> , 2022, 10, 1263.	2.1	10
672	Multimerization of Ebola GP1 mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
673	CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	3
674	Biotechnology applications in infectious disease. , 2022, , 115-129.		0
675	PROSPECTS OF LASSA FEVER CANDIDATE VACCINES. <i>African Journal of Infectious Diseases</i> , 2022, 16, 46-58.	0.5	2
676	Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings. <i>Vaccine</i> , 2022, 40, 5806-5813.	1.7	0
677	Enhanced <i>In Vitro</i> and <i>In Vivo</i> Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
678	Vaccine clinical trials in low- and middle-income countries: a brief review of standard, newer and proposed approaches. <i>Expert Review of Vaccines</i> , 0, , 1-8.	2.0	0
679	Gene Therapy Cargoes Based on Viral Vector Delivery. <i>Current Gene Therapy</i> , 2023, 23, 111-134.	0.9	5
680	Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
681	Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 91-102.	4.6	3

#	ARTICLE	IF	CITATIONS
682	Psychometric development of the COVID-19 vaccine misinformation scale and effects on vaccine hesitancy. <i>Preventive Medicine Reports</i> , 2023, 31, 102087.	0.8	1
683	Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study. <i>Vaccine</i> , 2022, , .	1.7	0
684	Overcoming Biopharmaceutical Interferents for Quantitation of Host Cell DNA Using an Automated, High-Throughput Methodology. <i>AAPS Journal</i> , 2023, 25, .	2.2	0
685	Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults. <i>Clinical and Experimental Immunology</i> , 0, , .	1.1	1
686	Investing in preparedness for rapid detection and control of epidemics: analysis of health system reforms and their effect on 2021 Ebola virus disease epidemic response in Guinea. <i>BMJ Global Health</i> , 2023, 8, e010984.	2.0	3
687	Vaccine Design Strategies: Pathogens to Genomes. , 2021, , 440-488.		0
688	Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. <i>Viruses</i> , 2023, 15, 698.	1.5	20
689	Recombinant viral hemorrhagic septicemia virus with rearranged genomes as vaccine vectors to protect against lethal betanodavirus infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
690	Application of DNA Replicons in Gene Therapy and Vaccine Development. <i>Pharmaceutics</i> , 2023, 15, 947.	2.0	2
691	Replicating-Competent VSV-Vectored Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 329-348.	0.8	2
692	Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
693	Progress in Epidemiology of Ebola Virus Disease. , 2022, , 101-120.		0
696	Viral vectors engineered for gene therapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , 1-41.	1.6	1
697	Public Health as a Paradigm for Happiness: Understanding Vaccine Impact. , 2023, , 97-112.		0
699	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
700	Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI). , 2023, , 172-190.e9.		0
701	Ebola Vaccines. , 2023, , 311-329.e6.		0
702	Regulation of Vaccines in Low- and Middle-Income Countries. , 2023, , 1671-1678.e1.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------